Unicycive Therapeutics, Inc. (UNCY)
| Market Cap | 114.49M +40.0% |
| Revenue (ttm) | n/a |
| Net Income | -35.22M |
| EPS | -1.56 |
| Shares Out | 27.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 551,362 |
| Open | 4.070 |
| Previous Close | 4.070 |
| Day's Range | 4.050 - 4.200 |
| 52-Week Range | 3.930 - 8.740 |
| Beta | 1.82 |
| Analysts | Strong Buy |
| Price Target | 28.40 (+591.0%) |
| Est. Earnings | Nov 11, 2026 |
About UNCY
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney inj... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for UNCY stock is "Strong Buy." The 12-month stock price target is $28.4, which is an increase of 591.00% from the latest price.
News
Kaplan Fox Reminds Unicycive Therapeutics, Inc. (UNCY) Investors to Seek a Leadership Role Before Deadline on November 2, 2026
New York, New York--(Newsfile Corp. - October 1, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Comp...
Unicycive Therapeutics appoints Manning to its Board of Directors
Unicycive Therapeutics (UNCY) announced the appointment of Meredith Manning, M.B.A., to its Board of Directors. Most recently, she served as Chief Commercial Officer of Soleno Therapeutics (SLNO) Publ...
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
MOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for pat...
Kaplan Fox Notifies Investors of Unicycive Therapeutics, Inc. (UNCY) of the Lead Plaintiff Deadline on November 2, 2026
New York, New York--(Newsfile Corp. - September 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "C...
Unicycive Therapeutics price target lowered to $13 from $15 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $13 from $15 and keeps a Buy rating on the shares after the company announced that it resubmitted…
Unicycive Therapeutics announces resubmission of NDA for OLC
Unicycive Therapeutics (UNCY) announced the resubmission of its New Drug Application, NDA, for oxylanthanum carbonate, OLC, the Company’s investigational oral phosphate binder for the treatment of hyp...
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
MOUNTAIN VIEW, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for pa...
Kaplan Fox Advises Unicycive Therapeutics, Inc. (UNCY) Investors to Act Before the Lead Plaintiff Deadline on November 2, 2026
New York, New York--(Newsfile Corp. - September 25, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "C...
UNCY Stockholders Have Rights – If You Lost Money Investing in Unicycive Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acqui...
Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Properly Inspect its Third-Party Vendor's Manufacturing Facility to Ensure it Resolved the FDA's Previously Noted Deficiencies
San Diego, California--(Newsfile Corp. - September 15, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased o...
Unicycive Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Oxylanthanum Carbonate is positioned as a best-in-class phosphate binder for dialysis patients, with regulatory approval delayed solely by a pending FDA inspection of a third-party vendor. Commercial and supply chain preparations are complete, and financial resources are sufficient for launch and operations into 2027.
Unicycive Therapeutics Slides: Corporate presentation
Unicycive Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
LOS ALTOS, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Co...
Unicycive Therapeutics price target raised to $15 from $13 at Benchmark
Benchmark analyst Bruce Jackson raised the firm’s price target on Unicycive Therapeutics (UNCY) to $15 from $13 and keeps a Speculative Buy rating on the shares. Unicycive’s second CRL again…
Unicycive Therapeutics reports Q2 EPS (6c), consensus (33c)
“We are focused on securing approval of oxylanthanum carbonate and remain confident in the efficacy and safety of OLC and in its potential to improve care for patients with hyperphosphatemia…
Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley
B. Riley analyst Mayank Mamtani lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $20 from $22 and keeps a Buy rating on the shares. The key Q2 disclosure…
Unicycive Therapeutics price target lowered to $25 from $37 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $25 from $37 and keeps a Buy rating on the shares to account for the second…
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
- Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor
Unicycive Therapeutics Quarterly report: Q2 2026
Unicycive Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Unicycive Therapeutics Earnings release: Q2 2026
Unicycive Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Unicycive Therapeutics Slides: Corporate presentation
Unicycive Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 31, 2026.
Unicycive Therapeutics price target lowered to $50 from $60 at Noble Capital
Noble Capital lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $50 from $60 and keeps an Outperform rating on the shares after the company announced it has received…
Unicycive Therapeutics price target lowered to $13 from $18 at Benchmark
Benchmark lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $13 from $18 and keeps a Speculative Buy rating on the shares after the company received a new Complete…
Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of investors who suffered losses and whether those losses may b...
Unicycive Therapeutics price target lowered to $15 from $22 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $15 from $22 and keeps a Buy rating on the shares after the company disclosed…